Results 211 to 220 of about 155,269 (289)
The power of many: when genetics met yeasts and high‐throughput
ABSTRACT In recent years, complex technological capabilities have evolved, driven by the need to solve complex and integrative biological questions through global analyses. New equipment allows the scaling up and automation of processes which previously were carried out on a very limited scale.
Víctor A. Tallada, Víctor Carranco
wiley +1 more source
Correction: Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics. [PDF]
Derbalah A +8 more
europepmc +1 more source
Pd(II)‐Catalyzed Strategies for the β‐Arylation of α‐Amino Acids: An Overview
The graphical abstract summarizes the review “Pd(II)‐Catalyzed Strategies for the β‐Arylation of α‐Amino Acids: An Overview”, highlighting representative Pd(II)‐catalyzed methods for the β‐arylation of α‐amino acids. Key mechanistic features, substrate diversity, and synthetic relevance of these transformations are showcased. Abstract Metal‐catalyzed C─
Davide Illuminati +4 more
wiley +1 more source
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik +3 more
wiley +1 more source
Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage. [PDF]
Niazi SK.
europepmc +1 more source
Over the past decade, the interest in azetidines has continuously risen, by virtue of their highly appealing pharmaceutical properties. Monocyclic, spirocyclic, and bridged azetidines can be accessed by leveraging 1‐azabicyclo[1.1.0]butanes as precursors.
Yuri Gelato +3 more
wiley +1 more source
Soothing a Ruffled Mind: Chronotherapy of Cushing Syndrome. [PDF]
Elenius H, Nieman LK.
europepmc +1 more source
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi +100 more
wiley +1 more source

